DISCLAIMER — Not financial advice. Educational content only, not an offer or solicitation to buy or sell any security. Biotech and small/mid-cap stocks are highly speculative and volatile and can result in a partial or total loss of capital. Do your own research and consult a licensed advisor where appropriate.
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Merlintrader Trading Pub
Biotech catalyst news and analysis. FDA PDUFA tracker
Category Reports Biotech
Tickers reports and analysis
GUTS Fractyl Health Inc Update jan 20
Fractyl Health is a small-cap metabolic therapeutics company listed on Nasdaq under the ticker GUTS. The company’s core bet is that a one-time endoscopic procedure on the duodenum, combined eventually with gene therapy, can offer a durable “off-ramp” for patients who need or want to come off GLP-1 drugs but would otherwise regain weight quickly.
SHPH Shuttle Pharmaceuticals Holdings Inc
The 2026 biotech landscape is increasingly bifurcated between traditional development stories and “tech-bio” platforms that use AI to de-risk and compress timelines. Shuttle Pharmaceuticals positions itself at this intersection: a small oncology company built around radiosensitizers and a newly acquired AI platform, Molecule.ai, targeting the problem of radio-resistant tumors and inefficient drug development.
CRVS Corvus Pharmaceuticals Inc
Corvus Pharmaceuticals is a clinical-stage biotech now almost entirely defined by soquelitinib, an oral, highly selective ITK inhibitor designed to “rebalance” T-cell responses. The drug sits at the intersection of two very different but complementary franchises: inflammatory skin disease (atopic dermatitis) and T-cell lymphomas (PTCL and related entities).
GERN Geron Corp
Geron enters 2026 as a newly minted commercial hematology company with one marketed product, RYTELO (imetelstat), and a late-stage program that could pivot the story from niche LR-MDS anemia to broader myelofibrosis survival if the Phase 3 IMpactMF study delivers.
IBRX ImmunityBio
Over the last few weeks ImmunityBio has done pretty much everything a biotech can do to light up screens: big revenue jump, new regulatory approvals and sexy cell-therapy data. The stock has reacted exactly the way you would expect in a heavily shorted name – vertical move, news sites still talking about it days later, social media on fire.
In this piece we are going to do something boring but necessary: stack all the verifiable positives (with links), then put them next to the very real risks. Only at the end we’ll talk about the “everybody is still pushing this story” part and why that’s exactly the moment when you want to cool your head.
Novocure’s TRIDENT Miss: Why the Glioblastoma Setback Matters for the $NVCR Pipeline
Novocure’s Phase 3 TRIDENT study did not show a statistically significant overall-survival advantage for starting Tumor Treating Fields earlier during chemoradiation in newly diagnosed glioblastoma. The result is not a collapse of the TTFields platform, but it is a serious reset for the near-term narrative: the company must now prove that its growth story can be carried by commercial execution, pancreatic cancer, brain metastases from NSCLC, and the next wave of combination trials.
ATOS Atossa Therapeutics Inc
Atossa Therapeutics is a small-cap, clinical-stage biotech built around a single platform asset, the oral selective estrogen receptor modulator (SERM) (Z)-endoxifen. Until 2025 the investment story was mostly about breast cancer treatment and risk reduction, but in the last few months the company has opened a new front in Duchenne muscular dystrophy (DMD).
OGN Organon & Co
The FDA has approved an extension of the indicated duration of Nexplanon (etonogestrel implant) up to 5 years for the prevention of pregnancy, versus the previous 3-year label. Nexplanon is the flagship long-acting reversible contraception (LARC) product of Organon and one of the core pillars of its Women’s Health division.
Weekly Recap and Briefing Jan 12-17
eek of 12–17 January 2026 – a structured overview of what is really moving markets, geopolitical risk and the most talked-about tickers.
NVAX Novavax Inc at JPM CC
Why this NVAX update after JPM 2026
Novavax is a rare case where the narrative matters almost as much as the numbers. The company went from “late Covid vaccine laggard” to “maybe dead”, then back to life thanks to a sequence of deals and restructurings. The 44th J.P. Morgan Healthcare Conference was the moment where CEO John Jacobs tried to lock in a new story: Novavax as a lean, partner-driven, Matrix-M platform company with a visible (not guaranteed) path to sustainability.
IBRX – CGON – ENGN – NMIBC bladder-sparing race
igh-risk non-muscle-invasive bladder cancer after failure of BCG has become one of the hottest oncology niches of 2025–2026. ImmunityBio with ANKTIVA is already on the market, while CG Oncology and enGene are coming fast with late-stage programs. This report compares mechanisms, clinical data, timelines and sentiment, so traders can look beyond the single name that is dominating the headlines in these weeks.
ASND Ascendis Pharma
Achondroplasia already has one FDA-approved therapy on the market (BioMarin’s Voxzogo), so TransCon CNP is a “second entrant” story. That means the regulatory decision matters, but so will positioning, differentiation, and adoption post-approval.
OCUL Ocular Therapeutix Inc
Daily Hit on Ocular Therapeutix after the latest spike on renewed takeover chatter and ahead of the 52-week phase 3 SOL-1 readout for AXPAXLI (suprachoroidal axitinib). Cash-heavy balance sheet, a single pivotal asset at the centre of the story, and a market now trying to price both M&A optionality and binary clinical risk.
IBRX ImmunityBio Inc Update jan 14
Deep-dive update on ImmunityBio after the Saudi Food and Drug Authority granted approval to ANKTIVA + BCG for BCG-unresponsive non-muscle invasive bladder cancer with carcinoma in situ, on top of existing approvals in the U.S., U.K. and conditional approval in the EU. Focus on the non-muscle invasive bladder cancer franchise, commercial trajectory, balance sheet and the next catalysts around QUILT-3.032 and QUILT-2.005.
OMER – Omeros – YARTEMLEA TA-TMA launch
Short update on Omeros after the FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA, the start of the U.S. launch and the analyst upgrades published in early January 2026. For the full story, background and detailed scenarios, see the main OMER reports on Merlintrader.
VKTX Viking Therapeutics Inc
Short update on VK2735 after the Phase 2 VENTURE data were published in the journal Obesity and after CEO Brian Lian’s comments at the J.P. Morgan Healthcare Conference 2026. For the full story, fundamentals and detailed scenarios, see the main VKTX report on Merlintrader.
BCTX BriaCell Therapeutics
BriaCell Therapeutics (BCTX) is the definition of a high-beta biotech: a tiny, heavily dilutive, clinical-stage immuno-oncology company with a real science story, now colliding head-on with a brutal funding reality. On January 13, 2026, the company reported an 11-month sustained complete resolution of a lung metastasis in a 78-year-old metastatic breast cancer patient treated with Bria-OTS in Phase 1/2a – no dose-limiting toxicities, stable disease at other sites, Phase 1 completed and Phase 2a combo underway. That headline sent the stock vertical.
Within hours, BriaCell followed up with a $30M best-efforts public unit offering at $5.59 per unit, each unit including one common share (or pre-funded) + one listed warrant at $6.93 (BCTXL) with five-year maturity. The market’s response: a pre-market gap down to ~$5.0, more than -50% vs the prior close at $10.92, and a reset of the whole technical picture.
NRXP NRX Pharmaceuticals Inc
NRx has licensed a nationwide Real-World Evidence dataset from Osmind covering more than 70,000 patients treated with IV ketamine or intranasal esketamine for major depression with suicidal ideation. The full analysis will be submitted to the FDA in support of an Accelerated Approval application for NRX-100, the preservative-free ketamine IV formulation already under Fast Track Designation for suicidal ideation in depression and bipolar depression.
TVTX Travere Therapeutics Inc UPDATE jan 13 PDUFA Extension to april 13 2026
Travere confirmed that the PDUFA date for the FILSPARI sNDA in FSGS is January 13, 2026. In the latest corporate update (press release) and at the JPM conference, management explained that the FDA recently sent a series of additional information requests “to further characterize the clinical benefit of FILSPARI” and that Travere has now submitted complete responses, which are under review.
XAIR Beyond Air Inc
Beyond Air (XAIR) – Nitric Oxide Platform, NeuroNOS Deal and LungFit PH Expansion | Merlintrader trading Blog IT EN Beyond Air (XAIR) – Nitric oxide platform, NeuroNOS deal and a 170% day Beyond Air (XAIR) is a commercial-stage medtech/biopharma company…